Strength Seen in IntelliPharmaCeutics (IPCI): Stock Shoots 161.9% - Tale of the Tape
November 20 2013 - 9:04AM
Zacks
IntelliPharmaCeutics International Inc. (IPCI) was
a big mover last session, as the company saw its shares shoot by
nearly 162% on the day. The move came on solid volume too with far
more shares changing hands than in a normal session as the company
gained the U.S. Food and Drug Administration’s approval to market
the generic version of attention deficit hyperactive disorder drug,
Focalin XR. The closing price represents a substantial jump from
the near-flat trading range of $1.68 to $2.00 in the past one-month
time frame.
This biopharmaceutical company has seen no estimate revisions in
the past 30 days and its Zacks Consensus Estimate has remained
unchanged. Yesterday’s price action is encouraging though, so make
sure to keep a close watch on this firm in the near future.
IntelliPharmaCeutics currently has a Zacks Rank #3 (Hold) and its
Earnings ESP is 0.00%.
Some better performing stocks in the same industry include
Lannett Company, Inc. (LCI),
Jazz
Pharmaceuticals Public Limited Company (JAZZ) and
Furiex Pharmaceuticals, Inc. (FURX). While Lannett
and Jazz carry a Zacks Rank #1 (Strong Buy), Furiex carries a Zacks
Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download
7 Best Stocks for the Next 30
Days. Click to get this free report >>
FURIEX PHARMACT (FURX): Free Stock Analysis Report
INTELLIPHARMACT (IPCI): Free Stock Analysis Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
London Clubs (AMEX:LCI)
Historical Stock Chart
From Jul 2024 to Aug 2024
London Clubs (AMEX:LCI)
Historical Stock Chart
From Aug 2023 to Aug 2024